Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Morgan McEwin

Nurse Practitioner, Acute Care Columbia, MO Nurse Practitioner

NPI 1417423286 CMS profile 11219450

One Hospital Dr, Columbia, MO 65212

Open in the dashboard

General payments

$3,427

36 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Morgan McEwin of Columbia, MO is reported in the CMS Open Payments database as having received $3,427 across 36 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Nurse Practitioner, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,886 23
2024 General $34 1
2022 General $36 2
2021 General $472 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Morgan McEwin
  • Nurse Practitioner, Acute Care median
  • Middle half of Nurse Practitioner, Acute Care
  • National median

In program year 2025, general payments to Morgan McEwin were reported at $2,886. Among 11,827 Nurse Practitioner, Acute Care profiles paid that year, the median was $152 and the middle half received between $48 and $458.

Show as a table
Year Morgan McEwin Nurse Practitioner, Acute Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $472 $123 $38–$327 $132
2022 $36 $130 $44–$369 $149
2023 $0 $144 $49–$410 $160
2024 $34 $146 $48–$433 $164
2025 $2,886 $152 $48–$458 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Atricure, Inc. $2,822 16 payments
  2. Lantheus Medical Imaging, Inc. $226 5 payments
  3. Edwards Lifesciences Corporation $101 3 payments
  4. Boston Scientific Corporation $55 1 payment
  5. Alnylam Pharmaceuticals Inc. $53 3 payments
  6. La Jolla Pharmaceutical Company $43 2 payments
  7. Medtronic, Inc. $35 2 payments
  8. Baxter Healthcare $32 1 payment
  9. Medical Device Business Services, Inc. $28 1 payment
  10. Chiesi USA, Inc. $16 1 payment
  11. Other $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Travel and Lodging $1,775 5 payments
  2. Food and Beverage $1,652 31 payments
Products named General payments · program years 2021–2025
  1. EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX $1,610 8 payments
  2. SYNERGY ABLATION SYSTEM $1,449 9 payments
  3. ATRICLIP LAA EXCLUSION SYSTEM $360 4 payments
  4. AtriCure cryoICE cryoSPHERE Cryoablation System $280 2 payments
  5. DEFINITY $226 5 payments
  6. ATRICURE CRYOICE CRYOABLATION SYSTEM (CRYO2) $150 1 payment
  7. SYNERGY $55 1 payment
  8. AMVUTTRA $53 3 payments
  9. INSPIRIS RESILIA AORTIC VALVE $47 1 payment
  10. GIAPREZA $43 2 payments
  11. Other $196 9 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

516

Median for Nurse Practitioner: 389

Drug cost

$17,366

Median for Nurse Practitioner: $21,885

Branded share of claims

16.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 13 $8,399
Eliquis Apixaban Brand 12 $7,131
Clopidogrel Clopidogrel Bisulfate Brand 62 $448
Metoprolol Tartrate Generic 86 $232
Amiodarone Hcl Generic 25 $221
Potassium Chloride Generic 63 $205
Atorvastatin Calcium Generic 48 $200
Oxycodone Hcl Generic 56 $195
Tramadol Hcl Generic 72 $160
Spironolactone Generic 21 $95

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$3,461

Medicare's payments for the services billed

Medicare patients

26

Average age 77

Services billed

35

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Heart failure 73%
Atrial fibrillation 62%
Chronic kidney disease 46%
Diabetes 42%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

36 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record